Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. Among authors: hebert la. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group. Fervenza FC, et al. Among authors: hebert la. Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12. Nephron. 2015. PMID: 26087670 Clinical Trial.
Mycophenolate therapy of SLE membranous nephropathy.
Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, Hebert LA. Spetie DN, et al. Among authors: hebert la. Kidney Int. 2004 Dec;66(6):2411-5. doi: 10.1111/j.1523-1755.2004.66030.x. Kidney Int. 2004. PMID: 15569333 Free article. Clinical Trial.
Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.
Barnes CE, Wilmer WA, Hernandez RA Jr, Valentine C, Hiremath LS, Nadasdy T, Satoskar AA, Shim RL, Rovin BH, Hebert LA. Barnes CE, et al. Among authors: hebert la. Nephron Clin Pract. 2011;119(2):c145-53. doi: 10.1159/000324762. Epub 2011 Jul 8. Nephron Clin Pract. 2011. PMID: 21757952 Free PMC article.
Uric acid and cardiovascular risk.
Hebert LA, Rovin B. Hebert LA, et al. N Engl J Med. 2009 Jan 29;360(5):540; author reply 540-1. N Engl J Med. 2009. PMID: 19186313 No abstract available.
192 results